Cocrystal Pharma Advances Norovirus Drug with FDA Fast Track Designation — Cocrystal Pharma, Inc.

Event summary

Completed enrollment in first cohort of Phase 1b challenge study for CDI-988, evaluating its efficacy as a preventive and treatment for norovirus infection.
Received FDA Fast Track designation for CDI-988, accelerating development pathway for the norovirus treatment.
Secured initial $225,000 of SBIR NIH grant for influenza A and B antiviral lead generation.
Reported Q1 2026 revenue of $225,000 from NIH SBIR award, with net loss of $2.3 million.

The big picture

Cocrystal Pharma is advancing its antiviral pipeline with significant milestones in norovirus treatment, leveraging FDA Fast Track designation to expedite development. The company's focus on broad-spectrum antivirals aligns with the growing need for effective treatments against highly contagious viruses like norovirus and influenza, which pose substantial public health and economic burdens.

What we're watching

Clinical Progress: The pace at which CDI-988 advances through Phase 1b trials will determine its viability as a norovirus treatment.
Funding Sustainability: Whether Cocrystal can secure additional non-dilutive funding to support further development of its antiviral pipeline.
Regulatory Advantage: How the FDA Fast Track designation will impact the acceleration and prioritization of CDI-988's development pathway.